Public health lawfully outlaws the patent rights: a story of March-in rights!
My previous posts on the open-source innovation read with Doha style compulsory licensing and revocation in the public interest were exhaustive on the access to […]
Compulsory licensing
From the bolar provision to the issuance of the compulsory license and revocation in the public interest – Remdesivir drug of Gilead is a complete course on patent law
The time since the experts have suggested “Remdesivir” as a possible drug to fight against COVID-19, global debate over obtaining this drug is started. The […]
Open Source Innovation in the pharmaceuticals: Is that all for public health?
Dear Readers, I hope you are reading this post in your good health and essentially operable outdoor conditions. In this unfortunate time, when the world […]